Short-term clinical efficacy analysis of lobaplatin in intraperitoneal perfusion chemotherapy during colorectal cancer surgery
Objective To explore short-term clinical efficacy of intraperitoneal perfusion chemotherapy u-sing loboplatin during colorectal cancer surgery.Methods Between September 2021 and December 2022,a total of 80 patients diagnosed with colorectal tumors who underwent surgical treatment were enrolled in the study at the Gastrointestinal Surgery Department of the Affiliated Hospital of Youjiang Medical University for Nationalities.They were randomly divided into two groups:the observation group(n=40)receiving intraper-itoneal perfusion chemotherapy and the control group(n=40)undergoing conventional surgery.Observations were made on the recovery of intestinal function,postoperative complications,toxic and side effects of chemo-therapy,and alterations in immune function.Additionally,both groups were followed up to record the inci-dence of recurrence and metastasis at 6 and 12 months postoperatively.Results When comparing the two groups in terms of general patient information,intestinal function recovery,postoperative complications,toxic effects of chemotherapy,and immune function,no significant differences were revealed(P＞0.05).Howev-er,regarding recurrence and metastasis at 12 months postoperatively,the observation group exhibited superior outcomes compared to the control group,with a statistically significant difference(P＜0.05).Conclusion The use of lobaplatin for intraperitoneal perfusion chemotherapy during colorectal cancer surgery does not im-pair the patient's immune function or gastrointestinal function,nor does it increase surgical complications.Moreover,it can effectively reduce the short-term recurrence rate,proving to be a safe and efficacious adjuvant therapy with favorable clinical outcomes.
万方数据
维普
